APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Cancer Immunotherapy Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cancer Immunotherapy Drug Market Outlook and Growth Opportunities 2026

Report ID 173974290421 December 2025193 pages

Choose your research edition.

Industry ResearchCancer Immunotherapy Drug Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Immunotherapy Drug Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Cancer Immunotherapy Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Immunotherapy Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Immunotherapy Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Cancer Immunotherapy Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cancer Immunotherapy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cancer Immunotherapy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Immunotherapy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cancer Immunotherapy Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cancer Immunotherapy Drug market include Novartis AG, Merck & Co., Inc., Jiangsu Hengrui Medicine Corporation, Pfizer, Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Roche Holding AG, Medimmune, LLC and Juno Pharmaceuticals Pty Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cancer Immunotherapy Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cancer Immunotherapy Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cancer Immunotherapy Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cancer Immunotherapy Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Cancer Immunotherapy Drug Segment by Company

Novartis AG

Merck & Co., Inc.

Jiangsu Hengrui Medicine Corporation

Pfizer, Inc.

Bristol-Myers Squibb Company

AstraZeneca plc

Roche Holding AG

Medimmune, LLC

Juno Pharmaceuticals Pty Ltd.

Incyte Corporation

Gilead Sciences, Inc. (Kite Pharma)

Celgene Corporation

bluebird bio, Inc.

BeiGene

Autolus Therapeutics plc

Cancer Immunotherapy Drug Segment by Type

T-Cell Stimulant

PDL-1 Inhibitor

PD-1 Inhibitor

CTLA Antibody

Cancer Immunotherapy Drug Segment by Application

Hospital

Clinic

Others

Cancer Immunotherapy Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Cancer Immunotherapy Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Cancer Immunotherapy Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cancer Immunotherapy Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Cancer Immunotherapy Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Immunotherapy Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Immunotherapy Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Immunotherapy Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cancer Immunotherapy Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cancer Immunotherapy Drug industry.

Chapter 3: Detailed analysis of Cancer Immunotherapy Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Cancer Immunotherapy Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Cancer Immunotherapy Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cancer Immunotherapy Drug Industry Trends Table 2. Cancer Immunotherapy Drug Industry Drivers Table 3. Cancer Immunotherapy Drug Industry Opportunities and Challenges Table 4. Cancer Immunotherapy Drug Industry Restraints Table 5. Global Cancer Immunotherapy Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cancer Immunotherapy Drug Revenue Share by Company (2021-2026) Table 7. Global Cancer Immunotherapy Drug Sales Volume by Company (k units) & (2021-2026) Table 8. Global Cancer Immunotherapy Drug Sales Volume Share by Company (2021-2026) Table 9. Global Cancer Immunotherapy Drug Average Price (US$/unit) of Company (2021-2026) Table 10. Global Cancer Immunotherapy Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Cancer Immunotherapy Drug Key Company Manufacturing Base & Headquarters Table 12. Global Cancer Immunotherapy Drug Company, Product Type & Application Table 13. Global Cancer Immunotherapy Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Cancer Immunotherapy Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of T-Cell Stimulant Table 18. Significant Companies of PDL-1 Inhibitor Table 19. Significant Companies of PD-1 Inhibitor Table 20. Significant Companies of CTLA Antibody Table 21. Global Cancer Immunotherapy Drug Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Cancer Immunotherapy Drug Sales Volume by Type (2021-2026) & (k units) Table 23. Global Cancer Immunotherapy Drug Sales Volume by Type (2027-2032) & (k units) Table 24. Global Cancer Immunotherapy Drug Sales Volume Share by Type (2021-2026) Table 25. Global Cancer Immunotherapy Drug Sales Volume Share by Type (2027-2032) Table 26. Global Cancer Immunotherapy Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Cancer Immunotherapy Drug Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Cancer Immunotherapy Drug Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Cancer Immunotherapy Drug Sales Value Share by Type (2021-2026) Table 30. Global Cancer Immunotherapy Drug Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Clinic Table 33. Significant Companies of Others Table 34. Global Cancer Immunotherapy Drug Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Cancer Immunotherapy Drug Sales Volume by Application (2021-2026) & (k units) Table 36. Global Cancer Immunotherapy Drug Sales Volume by Application (2027-2032) & (k units) Table 37. Global Cancer Immunotherapy Drug Sales Volume Share by Application (2021-2026) Table 38. Global Cancer Immunotherapy Drug Sales Volume Share by Application (2027-2032) Table 39. Global Cancer Immunotherapy Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Cancer Immunotherapy Drug Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Cancer Immunotherapy Drug Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Cancer Immunotherapy Drug Sales Value Share by Application (2021-2026) Table 43. Global Cancer Immunotherapy Drug Sales Value Share by Application (2027-2032) Table 44. Global Cancer Immunotherapy Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Cancer Immunotherapy Drug Sales by Region (2021-2026) & (k units) Table 46. Global Cancer Immunotherapy Drug Sales Market Share by Region (2021-2026) Table 47. Global Cancer Immunotherapy Drug Sales by Region (2027-2032) & (k units) Table 48. Global Cancer Immunotherapy Drug Sales Market Share by Region (2027-2032) Table 49. Global Cancer Immunotherapy Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Cancer Immunotherapy Drug Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Cancer Immunotherapy Drug Sales Value Share by Region (2021-2026) Table 52. Global Cancer Immunotherapy Drug Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Cancer Immunotherapy Drug Sales Value Share by Region (2027-2032) Table 54. Global Cancer Immunotherapy Drug Market Average Price (US$/unit) by Region (2021-2026) Table 55. Global Cancer Immunotherapy Drug Market Average Price (US$/unit) by Region (2027-2032) Table 56. Global Cancer Immunotherapy Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Global Cancer Immunotherapy Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Cancer Immunotherapy Drug Sales by Country (2021-2026) & (k units) Table 59. Global Cancer Immunotherapy Drug Sales Market Share by Country (2021-2026) Table 60. Global Cancer Immunotherapy Drug Sales by Country (2027-2032) & (k units) Table 61. Global Cancer Immunotherapy Drug Sales Market Share by Country (2027-2032) Table 62. Global Cancer Immunotherapy Drug Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Cancer Immunotherapy Drug Sales Value Market Share by Country (2021-2026) Table 64. Global Cancer Immunotherapy Drug Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Cancer Immunotherapy Drug Sales Value Market Share by Country (2027-2032) Table 66. Novartis AG Company Information Table 67. Novartis AG Business Overview Table 68. Novartis AG Cancer Immunotherapy Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 69. Novartis AG Cancer Immunotherapy Drug Product Portfolio Table 70. Novartis AG Recent Development Table 71. Merck & Co., Inc. Company Information Table 72. Merck & Co., Inc. Business Overview Table 73. Merck & Co., Inc. Cancer Immunotherapy Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Merck & Co., Inc. Cancer Immunotherapy Drug Product Portfolio Table 75. Merck & Co., Inc. Recent Development Table 76. Jiangsu Hengrui Medicine Corporation Company Information Table 77. Jiangsu Hengrui Medicine Corporation Business Overview Table 78. Jiangsu Hengrui Medicine Corporation Cancer Immunotherapy Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Jiangsu Hengrui Medicine Corporation Cancer Immunotherapy Drug Product Portfolio Table 80. Jiangsu Hengrui Medicine Corporation Recent Development Table 81. Pfizer, Inc. Company Information Table 82. Pfizer, Inc. Business Overview Table 83. Pfizer, Inc. Cancer Immunotherapy Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Pfizer, Inc. Cancer Immunotherapy Drug Product Portfolio Table 85. Pfizer, Inc. Recent Development Table 86. Bristol-Myers Squibb Company Company Information Table 87. Bristol-Myers Squibb Company Business Overview Table 88. Bristol-Myers Squibb Company Cancer Immunotherapy Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Bristol-Myers Squibb Company Cancer Immunotherapy Drug Product Portfolio Table 90. Bristol-Myers Squibb Company Recent Development Table 91. AstraZeneca plc Company Information Table 92. AstraZeneca plc Business Overview Table 93. AstraZeneca plc Cancer Immunotherapy Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. AstraZeneca plc Cancer Immunotherapy Drug Product Portfolio Table 95. AstraZeneca plc Recent Development Table 96. Roche Holding AG Company Information Table 97. Roche Holding AG Business Overview Table 98. Roche Holding AG Cancer Immunotherapy Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Roche Holding AG Cancer Immunotherapy Drug Product Portfolio Table 100. Roche Holding AG Recent Development Table 101. Medimmune, LLC Company Information Table 102. Medimmune, LLC Business Overview Table 103. Medimmune, LLC Cancer Immunotherapy Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. Medimmune, LLC Cancer Immunotherapy Drug Product Portfolio Table 105. Medimmune, LLC Recent Development Table 106. Juno Pharmaceuticals Pty Ltd. Company Information Table 107. Juno Pharmaceuticals Pty Ltd. Business Overview Table 108. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product Portfolio Table 110. Juno Pharmaceuticals Pty Ltd. Recent Development Table 111. Incyte Corporation Company Information Table 112. Incyte Corporation Business Overview Table 113. Incyte Corporation Cancer Immunotherapy Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. Incyte Corporation Cancer Immunotherapy Drug Product Portfolio Table 115. Incyte Corporation Recent Development Table 116. Gilead Sciences, Inc. (Kite Pharma) Company Information Table 117. Gilead Sciences, Inc. (Kite Pharma) Business Overview Table 118. Gilead Sciences, Inc. (Kite Pharma) Cancer Immunotherapy Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. Gilead Sciences, Inc. (Kite Pharma) Cancer Immunotherapy Drug Product Portfolio Table 120. Gilead Sciences, Inc. (Kite Pharma) Recent Development Table 121. Celgene Corporation Company Information Table 122. Celgene Corporation Business Overview Table 123. Celgene Corporation Cancer Immunotherapy Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 124. Celgene Corporation Cancer Immunotherapy Drug Product Portfolio Table 125. Celgene Corporation Recent Development Table 126. bluebird bio, Inc. Company Information Table 127. bluebird bio, Inc. Business Overview Table 128. bluebird bio, Inc. Cancer Immunotherapy Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 129. bluebird bio, Inc. Cancer Immunotherapy Drug Product Portfolio Table 130. bluebird bio, Inc. Recent Development Table 131. BeiGene Company Information Table 132. BeiGene Business Overview Table 133. BeiGene Cancer Immunotherapy Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 134. BeiGene Cancer Immunotherapy Drug Product Portfolio Table 135. BeiGene Recent Development Table 136. Autolus Therapeutics plc Company Information Table 137. Autolus Therapeutics plc Business Overview Table 138. Autolus Therapeutics plc Cancer Immunotherapy Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 139. Autolus Therapeutics plc Cancer Immunotherapy Drug Product Portfolio Table 140. Autolus Therapeutics plc Recent Development Table 141. Key Raw Materials Table 142. Raw Materials Key Suppliers Table 143. Cancer Immunotherapy Drug Distributors List Table 144. Cancer Immunotherapy Drug Customers List Table 145. Research Programs/Design for This Report Table 146. Authors List of This Report Table 147. Secondary Sources Table 148. Primary Sources List of Figures Figure 1. Cancer Immunotherapy Drug Product Image Figure 2. Global Cancer Immunotherapy Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Immunotherapy Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Cancer Immunotherapy Drug Sales (2021-2032) & (k units) Figure 5. Global Cancer Immunotherapy Drug Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Cancer Immunotherapy Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. T-Cell Stimulant Image Figure 10. PDL-1 Inhibitor Image Figure 11. PD-1 Inhibitor Image Figure 12. CTLA Antibody Image Figure 13. Global Cancer Immunotherapy Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Cancer Immunotherapy Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Cancer Immunotherapy Drug Sales Volume Share by Type (2021-2032) Figure 16. Global Cancer Immunotherapy Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Cancer Immunotherapy Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Cancer Immunotherapy Drug Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Others Image Figure 22. Global Cancer Immunotherapy Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Cancer Immunotherapy Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Cancer Immunotherapy Drug Sales Volume Share by Application (2021-2032) Figure 25. Global Cancer Immunotherapy Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Cancer Immunotherapy Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Cancer Immunotherapy Drug Sales Value Share by Application (2021-2032) Figure 28. Global Cancer Immunotherapy Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 29. Global Cancer Immunotherapy Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Cancer Immunotherapy Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Cancer Immunotherapy Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Cancer Immunotherapy Drug Sales Value (2021-2032) & (US$ Million) Figure 33. North America Cancer Immunotherapy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Cancer Immunotherapy Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Cancer Immunotherapy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Cancer Immunotherapy Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Cancer Immunotherapy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Cancer Immunotherapy Drug Sales Value (2021-2032) & (US$ Million) Figure 39. South America Cancer Immunotherapy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Cancer Immunotherapy Drug Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Cancer Immunotherapy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Cancer Immunotherapy Drug Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Cancer Immunotherapy Drug Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • T-Cell Stimulant
  • PDL-1 Inhibitor
  • PD-1 Inhibitor
  • CTLA Antibody
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis AG
  • Merck & Co., Inc.
  • Jiangsu Hengrui Medicine Corporation
  • Pfizer, Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • Roche Holding AG
  • Medimmune, LLC
  • Juno Pharmaceuticals Pty Ltd.
  • Incyte Corporation
  • Gilead Sciences, Inc. (Kite Pharma)
  • Celgene Corporation
  • bluebird bio, Inc.
  • BeiGene
  • Autolus Therapeutics plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Cancer Immunotherapy Drug Sales Value (2021-2032)
  4. 1.2.2 Global Cancer Immunotherapy Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Cancer Immunotherapy Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Cancer Immunotherapy Drug Market Dynamics
  1. 2.1 Cancer Immunotherapy Drug Industry Trends
  2. 2.2 Cancer Immunotherapy Drug Industry Drivers
  3. 2.3 Cancer Immunotherapy Drug Industry Opportunities and Challenges
  4. 2.4 Cancer Immunotherapy Drug Industry Restraints
3 Cancer Immunotherapy Drug Market by Company
  1. 3.1 Global Cancer Immunotherapy Drug Company Revenue Ranking in 2025
  2. 3.2 Global Cancer Immunotherapy Drug Revenue by Company (2021-2026)
  3. 3.3 Global Cancer Immunotherapy Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Cancer Immunotherapy Drug Average Price by Company (2021-2026)
  5. 3.5 Global Cancer Immunotherapy Drug Company Ranking (2024-2026)
  6. 3.6 Global Cancer Immunotherapy Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Cancer Immunotherapy Drug Company Product Type and Application
  8. 3.8 Global Cancer Immunotherapy Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Cancer Immunotherapy Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Cancer Immunotherapy Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Cancer Immunotherapy Drug Market by Type
  1. 4.1 Cancer Immunotherapy Drug Type Introduction
  2. 4.1.1 T-Cell Stimulant
  3. 4.1.2 PDL-1 Inhibitor
  4. 4.1.3 PD-1 Inhibitor
  5. 4.1.4 CTLA Antibody
  6. 4.2 Global Cancer Immunotherapy Drug Sales Volume by Type
  7. 4.2.1 Global Cancer Immunotherapy Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Cancer Immunotherapy Drug Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Cancer Immunotherapy Drug Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Cancer Immunotherapy Drug Sales Value by Type
  11. 4.3.1 Global Cancer Immunotherapy Drug Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Cancer Immunotherapy Drug Sales Value by Type (2021-2032)
  13. 4.3.3 Global Cancer Immunotherapy Drug Sales Value Share by Type (2021-2032)
5 Cancer Immunotherapy Drug Market by Application
  1. 5.1 Cancer Immunotherapy Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Cancer Immunotherapy Drug Sales Volume by Application
  6. 5.2.1 Global Cancer Immunotherapy Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cancer Immunotherapy Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Cancer Immunotherapy Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Cancer Immunotherapy Drug Sales Value by Application
  10. 5.3.1 Global Cancer Immunotherapy Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Cancer Immunotherapy Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Cancer Immunotherapy Drug Sales Value Share by Application (2021-2032)
6 Cancer Immunotherapy Drug Regional Sales and Value Analysis
  1. 6.1 Global Cancer Immunotherapy Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cancer Immunotherapy Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Cancer Immunotherapy Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Cancer Immunotherapy Drug Sales by Region (2027-2032)
  5. 6.3 Global Cancer Immunotherapy Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Cancer Immunotherapy Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Cancer Immunotherapy Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Cancer Immunotherapy Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Cancer Immunotherapy Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Cancer Immunotherapy Drug Sales Value (2021-2032)
  12. 6.6.2 North America Cancer Immunotherapy Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Cancer Immunotherapy Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Cancer Immunotherapy Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Cancer Immunotherapy Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Cancer Immunotherapy Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Cancer Immunotherapy Drug Sales Value (2021-2032)
  21. 6.9.2 South America Cancer Immunotherapy Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Cancer Immunotherapy Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Cancer Immunotherapy Drug Sales Value Share by Country, 2025 VS 2032
7 Cancer Immunotherapy Drug Country-level Sales and Value Analysis
  1. 7.1 Global Cancer Immunotherapy Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cancer Immunotherapy Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Cancer Immunotherapy Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Cancer Immunotherapy Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Cancer Immunotherapy Drug Sales by Country (2027-2032)
  6. 7.4 Global Cancer Immunotherapy Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Cancer Immunotherapy Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Cancer Immunotherapy Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Cancer Immunotherapy Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Cancer Immunotherapy Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Cancer Immunotherapy Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Cancer Immunotherapy Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Cancer Immunotherapy Drug Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Merck & Co., Inc.
  8. 8.2.1 Merck & Co., Inc. Company Information
  9. 8.2.2 Merck & Co., Inc. Business Overview
  10. 8.2.3 Merck & Co., Inc. Cancer Immunotherapy Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck & Co., Inc. Cancer Immunotherapy Drug Product Portfolio
  12. 8.2.5 Merck & Co., Inc. Recent Developments
  13. 8.3 Jiangsu Hengrui Medicine Corporation
  14. 8.3.1 Jiangsu Hengrui Medicine Corporation Company Information
  15. 8.3.2 Jiangsu Hengrui Medicine Corporation Business Overview
  16. 8.3.3 Jiangsu Hengrui Medicine Corporation Cancer Immunotherapy Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Jiangsu Hengrui Medicine Corporation Cancer Immunotherapy Drug Product Portfolio
  18. 8.3.5 Jiangsu Hengrui Medicine Corporation Recent Developments
  19. 8.4 Pfizer, Inc.
  20. 8.4.1 Pfizer, Inc. Company Information
  21. 8.4.2 Pfizer, Inc. Business Overview
  22. 8.4.3 Pfizer, Inc. Cancer Immunotherapy Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer, Inc. Cancer Immunotherapy Drug Product Portfolio
  24. 8.4.5 Pfizer, Inc. Recent Developments
  25. 8.5 Bristol-Myers Squibb Company
  26. 8.5.1 Bristol-Myers Squibb Company Company Information
  27. 8.5.2 Bristol-Myers Squibb Company Business Overview
  28. 8.5.3 Bristol-Myers Squibb Company Cancer Immunotherapy Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Bristol-Myers Squibb Company Cancer Immunotherapy Drug Product Portfolio
  30. 8.5.5 Bristol-Myers Squibb Company Recent Developments
  31. 8.6 AstraZeneca plc
  32. 8.6.1 AstraZeneca plc Company Information
  33. 8.6.2 AstraZeneca plc Business Overview
  34. 8.6.3 AstraZeneca plc Cancer Immunotherapy Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca plc Cancer Immunotherapy Drug Product Portfolio
  36. 8.6.5 AstraZeneca plc Recent Developments
  37. 8.7 Roche Holding AG
  38. 8.7.1 Roche Holding AG Company Information
  39. 8.7.2 Roche Holding AG Business Overview
  40. 8.7.3 Roche Holding AG Cancer Immunotherapy Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Roche Holding AG Cancer Immunotherapy Drug Product Portfolio
  42. 8.7.5 Roche Holding AG Recent Developments
  43. 8.8 Medimmune, LLC
  44. 8.8.1 Medimmune, LLC Company Information
  45. 8.8.2 Medimmune, LLC Business Overview
  46. 8.8.3 Medimmune, LLC Cancer Immunotherapy Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Medimmune, LLC Cancer Immunotherapy Drug Product Portfolio
  48. 8.8.5 Medimmune, LLC Recent Developments
  49. 8.9 Juno Pharmaceuticals Pty Ltd.
  50. 8.9.1 Juno Pharmaceuticals Pty Ltd. Company Information
  51. 8.9.2 Juno Pharmaceuticals Pty Ltd. Business Overview
  52. 8.9.3 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product Portfolio
  54. 8.9.5 Juno Pharmaceuticals Pty Ltd. Recent Developments
  55. 8.10 Incyte Corporation
  56. 8.10.1 Incyte Corporation Company Information
  57. 8.10.2 Incyte Corporation Business Overview
  58. 8.10.3 Incyte Corporation Cancer Immunotherapy Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Incyte Corporation Cancer Immunotherapy Drug Product Portfolio
  60. 8.10.5 Incyte Corporation Recent Developments
  61. 8.11 Gilead Sciences, Inc. (Kite Pharma)
  62. 8.11.1 Gilead Sciences, Inc. (Kite Pharma) Company Information
  63. 8.11.2 Gilead Sciences, Inc. (Kite Pharma) Business Overview
  64. 8.11.3 Gilead Sciences, Inc. (Kite Pharma) Cancer Immunotherapy Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Gilead Sciences, Inc. (Kite Pharma) Cancer Immunotherapy Drug Product Portfolio
  66. 8.11.5 Gilead Sciences, Inc. (Kite Pharma) Recent Developments
  67. 8.12 Celgene Corporation
  68. 8.12.1 Celgene Corporation Company Information
  69. 8.12.2 Celgene Corporation Business Overview
  70. 8.12.3 Celgene Corporation Cancer Immunotherapy Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Celgene Corporation Cancer Immunotherapy Drug Product Portfolio
  72. 8.12.5 Celgene Corporation Recent Developments
  73. 8.13 bluebird bio, Inc.
  74. 8.13.1 bluebird bio, Inc. Company Information
  75. 8.13.2 bluebird bio, Inc. Business Overview
  76. 8.13.3 bluebird bio, Inc. Cancer Immunotherapy Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 bluebird bio, Inc. Cancer Immunotherapy Drug Product Portfolio
  78. 8.13.5 bluebird bio, Inc. Recent Developments
  79. 8.14 BeiGene
  80. 8.14.1 BeiGene Company Information
  81. 8.14.2 BeiGene Business Overview
  82. 8.14.3 BeiGene Cancer Immunotherapy Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 BeiGene Cancer Immunotherapy Drug Product Portfolio
  84. 8.14.5 BeiGene Recent Developments
  85. 8.15 Autolus Therapeutics plc
  86. 8.15.1 Autolus Therapeutics plc Company Information
  87. 8.15.2 Autolus Therapeutics plc Business Overview
  88. 8.15.3 Autolus Therapeutics plc Cancer Immunotherapy Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Autolus Therapeutics plc Cancer Immunotherapy Drug Product Portfolio
  90. 8.15.5 Autolus Therapeutics plc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cancer Immunotherapy Drug Value Chain Analysis
  2. 9.1.1 Cancer Immunotherapy Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cancer Immunotherapy Drug Sales Mode & Process
  6. 9.2 Cancer Immunotherapy Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cancer Immunotherapy Drug Distributors
  9. 9.2.3 Cancer Immunotherapy Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst